Immune-Checkpoint Therapy Complications in the ICU: Clinical Challenges and Evidence-Based Management

Abstract

Immune-checkpoint inhibitors (ICIs) have transformed cancer therapy by unleashing the body's immune response against malignancies, yet their use is associated with a distinct spectrum of immune-related adverse events (irAEs). A subset of these complications necessitates intensive care unit (ICU) admission due to severity and multi-organ involvement. This review comprehensively examines the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, and management strategies for ICI-induced complications in the ICU. Clinically relevant insights and recent guideline-based recommendations are highlighted to enhance the care of critically ill patients receiving ICIs.

Introduction

Immune-checkpoint blockade, particularly with agents targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand (PD-L1), has revolutionized the management of various malignancies, including melanoma, non-small cell lung cancer, and renal cell carcinoma. As utilization has expanded across oncology, the spectrum and frequency of irAEs have become more apparent, with some toxicities leading to life-threatening organ dysfunction requiring ICU support. Intensivists and oncologists must be familiar with these complications to optimize outcomes through early recognition and evidence-based management.

Epidemiology / Disease Burden

Recent studies report that up to 20-30% of patients receiving ICIs develop moderate to severe irAEs, and approximately 2-5% require ICU-level care. The incidence and severity are influenced by the type of ICI, cancer type, combination regimens, and patient-specific factors. As indications for ICIs broaden and survival improves, ICU admissions related to irAEs are expected to rise. Pulmonary, cardiac, neurologic, and gastrointestinal toxicities are the predominant drivers of ICU transfer, often presenting with acute respiratory failure, myocarditis, encephalitis, or fulminant colitis.

Pathophysiology

ICIs disrupt the physiological balance between immune tolerance and activation by inhibiting checkpoint molecules that suppress T-cell activity. This potentiates anti-tumor immunity but can also provoke off-target, self-reactive immune responses. The immunopathogenesis of irAEs varies by organ, with T-cell infiltration, cytokine release, autoantibody production, and complement activation implicated. For example, ICI-induced myocarditis is characterized by lymphocytic infiltration and myocyte necrosis, while pneumonitis involves alveolar immune cell recruitment and diffuse parenchymal injury. The molecular mechanisms underlying patient susceptibility to severe irAEs remain an area of active research.

Risk Factors

Several risk factors predispose patients to severe or ICU-requiring irAEs. These include combination ICI therapy (e.g., anti-CTLA-4 plus anti-PD-1), prior autoimmune disease, baseline organ dysfunction, concurrent infections, older age, and certain genetic or immunologic backgrounds. Notably, patients with pre-existing cardiopulmonary disorders are particularly vulnerable to fulminant myocarditis or pneumonitis. Identification of high-risk patients is essential for early intervention and personalized monitoring strategies.

Clinical Features

The clinical presentation of ICI-related toxicities is highly variable and often non-specific, necessitating a high index of suspicion. Common ICU-relevant manifestations include acute dyspnea and hypoxemia (pneumonitis), chest pain, arrhythmias, and cardiogenic shock (myocarditis), seizures or encephalopathy (neurologic irAEs), and severe diarrhea or shock (colitis or adrenal crisis). Multi-organ involvement may occur simultaneously, complicating the clinical picture. Early symptoms may be subtle, and rapid progression to organ failure is possible, underscoring the need for vigilant monitoring in susceptible patients.

Diagnosis

Diagnosis of ICI-induced complications is challenging due to overlapping features with infectious, malignant, or paraneoplastic processes. A structured diagnostic approach includes detailed clinical assessment, laboratory evaluation for inflammatory and organ-specific markers, imaging (e.g., chest CT for pneumonitis, cardiac MRI for myocarditis), and, where appropriate, tissue biopsy. Microbiological workup is mandatory to exclude infection. Recent advances, such as circulating cytokine profiling and immune cell phenotyping, are being explored to improve diagnostic specificity.

Treatment & Management

Management of severe irAEs in the ICU is multidisciplinary and tailored to the affected organ(s). Immediate discontinuation of ICI therapy is standard. High-dose systemic corticosteroids (e.g., methylprednisolone 1-2 mg/kg/day) are the first-line treatment for most severe irAEs. Steroid-refractory cases may require additional immunosuppression with agents such as infliximab (for colitis), mycophenolate mofetil, intravenous immunoglobulin, or plasmapheresis (for neurologic or cardiac involvement). Supportive ICU care, including advanced hemodynamic or respiratory support, is often necessary. Early involvement of organ-specific specialists (e.g., cardiology, pulmonology, neurology, gastroenterology) is critical for optimal outcomes.

Recent Advances / Emerging Therapies

Emerging research has focused on optimizing immunosuppressive regimens to balance irAE control with cancer outcomes. Biomarkers such as IL-6, troponin, and autoantibody profiles are under investigation for early identification and risk stratification. Novel immunomodulatory agents, including Janus kinase inhibitors and anti-IL-6 therapies, are being evaluated in refractory cases. Consensus guidelines now recommend multidisciplinary irAE management pathways and highlight the importance of ICU-specific protocols for rapid escalation of care and infection prevention in immunosuppressed patients.

Guideline Recommendations

International guidelines from the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and Society for Immunotherapy of Cancer (SITC) provide structured approaches to irAE management. Key recommendations include prompt recognition of severe complications, early corticosteroid initiation, infection exclusion, and a stepwise escalation of immunosuppression. Guidelines emphasize individualized decision-making regarding ICI rechallenge after severe irAEs and advocate for patient education and close post-ICU follow-up to monitor for late sequelae.

Conclusion

ICU complications associated with immune-checkpoint therapy represent a growing clinical challenge in oncology. Prompt recognition, accurate diagnosis, and evidence-based management are essential to optimize outcomes in these critically ill patients. As our understanding of irAE pathogenesis and risk stratification evolves, incorporation of multidisciplinary guidelines and emerging therapies will enhance the safety and effectiveness of ICI treatment in high-risk populations.